JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms - sprookjes - yvandenbroek - TriplyDB

JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms

JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms

http://www.wikidata.org/entity/Q37168138

about

The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells.Rationally Repurposing Ruxolitinib (Jakafi (®)) as a Solid Tumor Therapeutic Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS Identification of myeloproliferative neoplasm drug agents via predictive simulation modeling: assessing responsiveness with micro-environment derived cytokines.STAT3 in Cancer-Friend or Foe?Personalized medicine in hematology - A landmark from bench to bed A comprehensive review of pacritinib in myelofibrosis.Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands.Snail-regulated MiR-375 inhibits migration and invasion of gastric cancer cells by targeting JAK2.CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview.Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma

P2860

Q35743852-4354CD45-AFFF-433E-A8B5-B9C7DA0F24AD Q36995729-C6B8CA22-2251-4A55-9202-3E1A6BDD62FB Q37109457-266AC97D-B49C-498C-902D-378E732D9BE8 Q37392623-C34DED9E-808E-47CD-BD9E-4F345DFCF090 Q38226313-5C069F61-3100-444D-B379-23E24AD59F60 Q38263199-B0F47EF7-4DA9-467A-AE7D-13F14D614041 Q38586421-65177660-6915-44CE-BA80-9893C1BE4D2B Q38625843-4287F815-7C07-4CB9-866B-6134307DA96F Q38972399-E6A52500-7476-43B5-BCC5-853D15FEAE04 Q41553248-6522D020-891F-4CCB-90B9-B150A72ECDD2 Q43122604-13992270-DACB-4D17-ACC0-2A957F151383 Q58742961-7634FE98-C8EE-46D3-932F-E05B0A880CA2

P2860

JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms

http://www.wikidata.org/entity/Q37168138

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 14 May 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

JAK2 mutants (e.g., JAK2V617F) ...... n myeloproliferative neoplasms

@en

JAK2 mutants (e.g., JAK2V617F) ...... myeloproliferative neoplasms.

@nl

type

label

JAK2 mutants (e.g., JAK2V617F) ...... n myeloproliferative neoplasms

@en

JAK2 mutants (e.g., JAK2V617F) ...... myeloproliferative neoplasms.

@nl

prefLabel

JAK2 mutants (e.g., JAK2V617F) ...... n myeloproliferative neoplasms

@en

JAK2 mutants (e.g., JAK2V617F) ...... myeloproliferative neoplasms.

@nl

P1433

Q37168138-5BC224D4-80AF-4CD6-8A38-90CDF6E93F99

P1476

Q37168138-3BBDA901-9D7F-4C82-918D-C7C7E8C1259F

P2093

Q37168138-AB5226F2-8CC3-4C1F-9FB7-23849CBB59D6

Q37168138-B32F8FD7-BA1B-4510-A7C0-1DD4C60C4C3A

Q37168138-B7EDDF79-59EC-4117-94B0-0CEBDD839445

P2860

Q37168138-01781EED-5376-43B3-B516-2F8E961045B1

Q37168138-01A0F5D8-F387-4410-9D93-D3F450C7A9C7

Q37168138-0336E1E6-E58E-4319-B040-F3B0068EE7EA

Q37168138-0362B250-77FD-48DB-8200-C3A5D2A93E48

Q37168138-0688F72C-838C-4C15-83EE-F067593FAAF0

Q37168138-07584FFA-73DF-417B-BAC8-5CC4A9C8E000

Q37168138-07D9B218-61F8-4BC8-ACC1-59E87BA30D13

Q37168138-080CEC0B-73A7-4E21-99EE-CC153F5824A2

Q37168138-089B1C6F-DBE7-458C-8EB5-DF5CF11EE40B

Q37168138-0958C117-2497-4835-9E26-485E4D0B0C7F

P304

Q37168138-19118B57-02D4-4727-ADBF-C3ACC63C77F3

P31

Q37168138-12F161B6-8275-46E4-9DA0-EB828209B1A3

P356

Q37168138-6EF4D30D-9395-4843-8B2F-0E4C45DF3A90

P433

Q37168138-1F81149B-1B63-48A8-A886-51BC3D05F88B

P478

Q37168138-C753BF1E-B7B8-433C-A298-C1929C35ECFD

P577

Q37168138-F7BE30BA-E84E-4E12-AC3B-839708C1AE74

P5875

Q37168138-6F3A8645-98F6-4EFE-9879-1E98C3172675

P698

Q37168138-E42F072E-3117-485D-8E02-0223D72E0918

P932

Q37168138-1D8F9D9C-12AC-4C19-9EC0-B107CF874B6A

P356

P1433

P1476

JAK2 mutants (e.g., JAK2V617F) ...... n myeloproliferative neoplasms

@en

P2093

Claude Haan

http://www.w3.org/2001/XMLSchema#string

Iris Behrmann

http://www.w3.org/2001/XMLSchema#string

Karoline Gäbler

http://www.w3.org/2001/XMLSchema#string

P2860

APS, an adaptor protein containing Pleckstrin homology (PH) and Src homology-2 (SH2) domains inhibits the JAK-STAT pathway in collaboration with c-Cbl

Hallmarks of Cancer: The Next Generation

Phosphorylation of p27Kip1 by JAK2 directly links cytokine receptor signaling to cell cycle control

Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase

Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis

JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin

Kinase activation through dimerization by human SH2-B

Principles of interleukin (IL)-6-type cytokine signalling and its regulation

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction

P304

e25025

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/JKST.25025

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257075957

http://www.w3.org/2001/XMLSchema#string

P698

24069563

http://www.w3.org/2001/XMLSchema#string

P932

3772115

http://www.w3.org/2001/XMLSchema#string